Provided by Tiger Trade Technology Pte. Ltd.

Xeris Pharmaceuticals Inc

8.74
+0.04000.46%
Post-market: 8.740.00000.00%16:10 EDT
Volume:870.74K
Turnover:7.59M
Market Cap:1.59B
PE:-85.68
High:8.80
Open:8.66
Low:8.54
Close:8.70
52wk High:10.08
52wk Low:5.25
Shares:182.32M
Float Shares:172.57M
Volume Ratio:0.47
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1020
EPS(LYR):0.0032
ROE:-617.16%
ROA:6.13%
PB:-163.70
PE(LYR):2,725.29

Loading ...

Sector Update: Health Care Stocks Fall Premarket Monday

MT Newswires Live
·
Mar 02

Stock Track | Xeris Pharmaceuticals Soars 7.84% in Pre-Market on Strong Q4 Earnings and Upbeat Guidance

Stock Track
·
Mar 02

GUIDANCE: (XERS) Xeris Biopharma Expects 2026 Total Revenue Range $375M to $390M, vs. FactSet Est of $368M

MT Newswires Live
·
Mar 02

Earnings Flash (XERS) Xeris Biopharma Posts Q4 EPS $0.06, vs. FactSet Est of $0.02

MT Newswires Live
·
Mar 02

Xeris Biopharma Holdings Q4 EPS $0.06 Beats $0.04 Estimate, Sales $85.807M Beat $82.340M Estimate

Benzinga Earnings
·
Mar 02

Xeris posts Q4 Recorlev net revenue of USD 45.3 million up 2.0x

Reuters
·
Mar 02

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

THOMSON REUTERS
·
Mar 02

Xeris Biopharma Q4 Product Revenue USD 83.43 Million VS. Ibes Estimate USD 82.3 Million

THOMSON REUTERS
·
Mar 02

Xeris Biopharma Holdings Inc FY2026 REV View $368.1 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Mar 02

Xeris Biopharma Q4 EPS USD 0.06

THOMSON REUTERS
·
Mar 02

Xeris Biopharma Q4 Operating Income USD 16.773 Million

THOMSON REUTERS
·
Mar 02

Xeris Biopharma Holdings Inc - Expects 2026 Revenue Between $375 Mln and $390 Mln

THOMSON REUTERS
·
Mar 02

A Look At Xeris Biopharma Holdings (XERS) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Feb 28

Why Are Shares Of Xeris Biopharma Falling Friday?

Benzinga_recent_news
·
Feb 28

BRIEF-Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit

Reuters
·
Feb 27

Xeris Biopharma Subsidiaries Sue Torrent and Somerset Over Recorlev Patents Through 2040

Reuters
·
Feb 27

Xeris Biopharma Holdings Inc: Intends to Enforce and Defend Its Intellectual Property Rights Relating to Recorlev

THOMSON REUTERS
·
Feb 27